Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.73 USD
−83.98 M USD
0.00 USD
36.26 M
About Apogee Therapeutics, Inc.
Sector
Industry
CEO
Michael Henderson
Website
Headquarters
Waltham
Founded
2022
FIGI
BBG01H51WYQ5
Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of APGE is 45.04 USD — it has increased by 2.63% in the past 24 hours. Watch Apogee Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Apogee Therapeutics, Inc. stocks are traded under the ticker APGE.
APGE stock has fallen by −22.78% compared to the previous week, the month change is a −17.09% fall, over the last year Apogee Therapeutics, Inc. has showed a 154.03% increase.
We've gathered analysts' opinions on Apogee Therapeutics, Inc. future price: according to them, APGE price has a max estimate of 100.00 USD and a min estimate of 75.00 USD. Watch APGE chart and read a more detailed Apogee Therapeutics, Inc. stock forecast: see what analysts think of Apogee Therapeutics, Inc. and suggest that you do with its stocks.
APGE reached its all-time high on Mar 13, 2024 with the price of 72.29 USD, and its all-time low was 14.19 USD and was reached on Nov 10, 2023. View more price dynamics on APGE chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
APGE stock is 5.25% volatile and has beta coefficient of 2.21. Track Apogee Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Apogee Therapeutics, Inc. there?
Today Apogee Therapeutics, Inc. has the market capitalization of 2.72 B, it has decreased by −2.48% over the last week.
Yes, you can track Apogee Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Apogee Therapeutics, Inc. is going to release the next earnings report on Mar 11, 2025. Keep track of upcoming events with our Earnings Calendar.
APGE earnings for the last quarter are −0.86 USD per share, whereas the estimation was −0.88 USD resulting in a 2.16% surprise. The estimated earnings for the next quarter are −1.06 USD per share. See more details about Apogee Therapeutics, Inc. earnings.
Apogee Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
APGE net income for the last quarter is −49.02 M USD, while the quarter before that showed −33.82 M USD of net income which accounts for −44.96% change. Track more Apogee Therapeutics, Inc. financial stats to get the full picture.
No, APGE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, APGE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Apogee Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Apogee Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Apogee Therapeutics, Inc. stock shows the sell signal. See more of Apogee Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.